Skip to main content

Table 2 The clinical application of combination of IP chemotherapy and systematic chemotherapy for gastric cancer patients with peritoneal metastasis

From: Issues on peritoneal metastasis of gastric cancer: an update

Authors

reference

Year

Country

Patients

N

IP

therapy

Systemic

therapy

MST

(m)

1-year

OS (%)

R0 resection (%)

Yamaguchi [51]

2013

Japan

GC patients with PM

35

PTX

PTX+S1

17.6

77.1

60.0

Kitayama [52]

2014

Japan

GC patients with PM

64

PTX

PTX+S1

26.4

82.0

53.1

Badgwell [57]

2017

USA

GC patients with PM

19

HIPEC

MMC and CDDP

5-Fu+

oxaliplatin

30.2

94.7

26.3

Yonemura [6]

2017

Japan

GC patients with PM

52

HIPEC

DTX and CDDP

DTX, CDDP and S1

19.2

-

57.6

  1. CDDP, cisplatin; DTX, docetaxel; HIPEC, hyperthermic intraperitoneal chemoperfusion; MMC, mitomycin C; PTX, paclitaxel